Editas Medicine (EDIT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individua ...

CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial results and business updates on May 12 via press release and SEC filings. As previously announced, the Company does not plan to host quarterly financial results conference calls moving forward. Additionally, Editas Medicine management will participate in the f ...

Core Insights - Editas Medicine announced the acceptance of five abstracts for presentation at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), highlighting its advancements in in vivo gene editing medicines [1][2] Company Developments - The company is making significant progress in preclinical development of in vivo medicines aimed at serious diseases, with a focus on gene upregulation editing strategies [2] - Editas Medicine will present preclinical data that demonstrates its ability to increase protein levels to address diseases caused by genetic mutations [2][4] - The presentations will include proof of concept data from studies using targeted lipid nanoparticles (tLNPs) for delivering gene editing cargo to hematopoietic stem cells [4][5] Presentation Details - An oral presentation titled "In Vivo Delivery of HBG1/2 Promoter Editing Cargo to HSC of Humanized Mouse and Non-Human Primate with Lipid Nanoparticles" is scheduled for May 14, 2025 [3] - Multiple poster presentations will also take place, covering topics such as improved LNP targeting ligands and the design of modified guide RNAs for enhanced gene editing potency [3][5] Research Focus - The research emphasizes in vivo CRISPR editing capabilities, aiming to upregulate target protein expression and reduce disease-associated biomarkers in relevant animal models [4][5] - Editas Medicine is leveraging its exclusive licenses for CRISPR/Cas12a and Cas9 technologies to develop a robust pipeline of transformative gene editing medicines [6]

Core Viewpoint - Editas Medicine has experienced a significant decline in share price, losing approximately 37.1% over the past month, underperforming the S&P 500, raising questions about its future performance leading up to the next earnings release [1] Group 1: Earnings Estimates - Fresh estimates for Editas have trended upward in the past month, with the consensus estimate shifting by 16.77% [2] Group 2: VGM Scores - Editas currently holds a subpar Growth Score of D, a strong Momentum Score of A, and a poor Value Score of F, resulting in an overall aggregate VGM Score of F [3] Group 3: Outlook - The upward trend in estimates for Editas appears promising, with a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [4] Group 4: Industry Performance - Editas is part of the Zacks Medical - Biomedical and Genetics industry, where Pacira (PCRX) has gained 1.8% over the past month, reporting revenues of $187.25 million, a year-over-year increase of 3.3% [5] - Pacira is expected to report earnings of $0.61 per share for the current quarter, reflecting a year-over-year decline of 1.6%, with a Zacks Rank of 3 (Hold) and a VGM Score of B [6]

Core Points - Editas Medicine announced that CFO Erick J. Lucera will step down effective March 28, 2025, to pursue another opportunity, with Amy Parison appointed as the new CFO [1][2][3] Company Leadership Transition - Amy Parison has been promoted to CFO after serving as Senior Vice President of Finance for two and a half years, demonstrating strong financial decision-making and leadership skills [2][4] - Dr. Gilmore O'Neill, President and CEO, expressed confidence in Parison's ability to lead the company financially and continue its mission of developing innovative medicines [2][3] Contributions and Experience - Lucera's contributions included positioning Editas financially and focusing on talent development, which helped prepare Parison for her new role [3][4] - Parison has over 18 years of experience in finance and accounting within the life sciences sector, having held various roles at Editas and previously at Rubius Therapeutics and Vertex Pharmaceuticals [4] Company Overview - Editas Medicine is a pioneering gene editing company focused on developing in vivo medicines using CRISPR technology to treat serious diseases [5]

Core Insights - Editas Medicine reported a wider loss of 55 cents per share in Q4 2024, compared to the Zacks Consensus Estimate of a loss of 39 cents, and a loss of 23 cents per share in the same quarter last year [1][9] - The company's total revenues for Q4 2024 were $30.6 million, down 49% from $60 million in Q4 2023, missing the Zacks Consensus Estimate of $38 million [2][9] - Editas' stock is declining in pre-market trading due to weaker-than-expected earnings results [3] Financial Performance - R&D expenses decreased by 30% to $48.6 million in Q4 2024 from $69.6 million in Q4 2023, attributed to prior sublicense payments to Vertex Pharmaceuticals [4] - General and administrative expenses rose by 13% year-over-year to $16.4 million due to increased professional service costs [4] - Restructuring charges amounted to $12.2 million in the quarter due to the discontinuation of the reni-cel program and workforce reduction, with no such charges recorded in the previous year [5] Cash Position - As of December 31, 2024, Editas had cash, cash equivalents, and investments totaling $269.9 million, up from $265.1 million as of September 30, 2024 [6] - The company expects its cash reserves to fund operations and capital expenditures into Q2 2027, with estimated total expenses of approximately $45-$55 million covering the termination of the reni-cel program [6] Market Performance - Editas shares have declined by 8.1% over the past three months, compared to a 2.3% decline in the industry [7] Strategic Updates - Editas has no approved products and is focusing on pipeline development, having ended the reni-cel program in December 2024 due to the lack of a commercial partner [10] - The company is prioritizing in vivo pipeline development, with plans to announce an in vivo hematopoietic stem cell development candidate by mid-2025 [12][13] - Editas has demonstrated effective gene editing in hematopoietic stem cells and liver cells, with further data expected by the end of 2025 [13][14] Licensing and Collaborations - In late 2023, Vertex Pharmaceuticals in-licensed rights to Editas' Cas9 gene editing tool for its sickle cell disease gene therapy [8] - Editas received $57 million in upfront cash from the sale of future license fees related to its Cas9 license agreement with Vertex [8]

Core Insights - Editas Medicine reported a quarterly loss of $0.55 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.39, and compared to a loss of $0.23 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $30.6 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 19.18% and down from $60.05 million year-over-year, reflecting ongoing challenges in meeting revenue expectations [2] - Editas shares have increased by approximately 38.6% since the beginning of the year, contrasting with a decline of 1.8% in the S&P 500, suggesting a relative outperformance in the market [3] Earnings Outlook - The earnings outlook for Editas is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.59 on revenues of $1.07 million, and for the current fiscal year at -$1.66 on revenues of $9.32 million, indicating continued expected losses [7] - The company currently holds a Zacks Rank 3 (Hold), suggesting that shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Editas belongs, is currently in the top 30% of over 250 Zacks industries, indicating a favorable industry outlook that could positively influence stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could be a useful metric for investors [5]

Financial Performance - The company reported net losses of $237.1 million, $153.2 million, and $220.4 million for the years ended December 31, 2024, 2023, and 2022 respectively, with an accumulated deficit of $1.5 billion as of December 31, 2024[587]. - The net loss for the year ended December 31, 2024, was $237.1 million, compared to a net loss of $153.2 million in 2023, reflecting a 55% increase in losses[608]. - The net loss for 2024 was $237.1 million, compared to a net loss of $153.2 million in 2023, indicating a worsening of approximately 55%[662]. - The company reported a net loss per share of $2.88 for 2024, compared to $2.02 for 2023, indicating a deterioration in per-share performance[662]. - Total liabilities rose from $150.1 million in 2023 to $207.3 million in 2024, an increase of approximately 38%[659]. - The accumulated deficit increased to $1.47 billion in 2024 from $1.23 billion in 2023, reflecting a growth of about 19%[659]. - The total stockholders' equity decreased significantly from $349.1 million in 2023 to $134.3 million in 2024, a decline of approximately 62%[659]. Revenue Generation - The company has not generated any revenue from product sales to date and does not expect to do so for the foreseeable future[588]. - In 2024, the company recognized $18.1 million of revenue related to its collaboration with BMS, with $6.5 million being previously deferred revenue[589]. - Collaboration and other research and development revenues decreased by $45.8 million, to $32.3 million for the year ended December 31, 2024, from $78.1 million for the year ended December 31, 2023, a decline of 59%[609]. - The company has not recognized any royalty revenue from collaboration or strategic alliance arrangements to date[704]. Research and Development - The company expects research and development expenses to increase significantly as it continues its preclinical studies and prepares for clinical development[596]. - Research and development expenses increased by $21.6 million, to $199.2 million for the year ended December 31, 2024, representing a 12% increase from $177.7 million in 2023[610]. - Employee-related expenses within research and development increased by 15%, from $47.4 million in 2023 to $54.2 million in 2024[610]. - External research and development expenses surged by 47%, from $53.3 million in 2023 to $78.5 million in 2024[610]. - The company anticipates a decrease in expenses over the next few years due to the discontinuation of the reni-cel program, but will continue to incur significant expenses for research and development[631]. Cash Flow and Liquidity - Net cash used in operating activities was approximately $210.3 million for the year ended December 31, 2024, compared to $132.2 million in 2023, primarily due to increased research efforts and clinical activities[624][625]. - The company expects its existing cash and marketable securities will fund operations into the second quarter of 2027, but significant additional funding will be needed for ongoing research and development[632]. - The company had cash, cash equivalents, and marketable securities totaling $269.9 million as of December 31, 2024[678]. - The company raised an aggregate of $1.0 billion in net proceeds through public offerings and had cash, cash equivalents, and marketable securities of $269.9 million[618][620]. - Cash flow from investing activities for 2024 was $162.1 million, compared to a net cash used of $3.7 million in 2023[671]. Expenses and Charges - General and administrative expenses rose by approximately $2.3 million, to $72.0 million for the year ended December 31, 2024, a 3% increase from $69.7 million in 2023[611]. - Restructuring charges amounted to $12.2 million for the year ended December 31, 2024, with no equivalent charges in 2023, marking a 100% increase[615]. - The Company recorded $21,000,000 in operating lease costs for the year ended December 31, 2024, compared to $15,200,000 in 2023, marking a 38.0% increase[748]. Collaborations and Agreements - The company has entered into a collaboration and license agreement in 2024 to access LNPs targeting the liver, enhancing its gene editing platform[583]. - The 2024 Amendment to the collaboration agreement with BMS extends the partnership to November 2026, allowing BMS to select up to three new gene targets for research[768]. - The total transaction price under the 2024 Amendment is approximately $56.7 million, with no milestone or extension term fees included as of December 31, 2024[771]. - The Company has granted Beam Therapeutics an exclusive license for the development and commercialization of base editing therapies, with options for additional licenses[775]. Market and Risk Factors - The company is exposed to market risk related to changes in interest rates, with cash and cash equivalents of $131.5 million and marketable securities of $138.4 million as of December 31, 2024[642]. - The Company has not experienced any credit losses and did not have an allowance for credit losses as of December 31, 2024 and 2023[691]. - The Company has not had any write-offs of bad debt and did not have an allowance for doubtful accounts as of December 31, 2024 and 2023[692]. Asset Management - Total current assets decreased from $340.8 million in 2023 to $289.3 million in 2024, a decline of approximately 15%[659]. - The Company recorded cash equivalents and marketable securities totaling $269,913,000 as of December 31, 2024, compared to $427,135,000 as of December 31, 2023, indicating a decrease of approximately 37%[740]. - The Company holds no securities with remaining maturities greater than one year as of December 31, 2024[742].

Preclinical Developments - Achieved in vivo preclinical proof of concept for editing hematopoietic stem cells in non-human primates, a key step towards developing treatments for sickle cell disease and beta thalassemia [4] - Demonstrated effective delivery and meaningful levels of editing in HSCs using proprietary targeted lipid nanoparticles after a single dose in non-human primates [7] - Achieved proof of concept in non-human primates validating high efficiency gene editing in the liver with the first use of AsCas12a delivery by LNP [7] Future Milestones - Anticipated 2025 milestones include declaring two in vivo development candidates, one in HSCs and one in liver, and presenting further in vivo data in both HSCs and liver indications [4] - Expected to establish an additional in vivo target cell type/tissue beyond HSCs and liver by the end of 2025 [8] - Expected to launch clinical trials for multiple in vivo programs, including submitting at least one IND/CTA by mid-2026 [13] Strategic Priorities - Strategic priorities through 2027 include submitting at least one IND/CTA and achieving human in vivo proof of concept in HSC editing for sickle cell disease and beta thalassemia [4] - Company plans to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, discussing new in vivo preclinical data and strategic priorities [11] Financial Position - Company has approximately $270 million in cash, cash equivalents, and marketable securities as of December 31, 2024, with a cash runway extending into Q2 2027 [10] - Company aims to derive additional value from its foundational CRISPR IP through sublicensing and monetization financing [8]

Core Insights - Editas Medicine is on track to declare two in vivo editing development candidates by mid-2025, one targeting hematopoietic stem cells (HSCs) and the other targeting liver cells [1][2] - The company has demonstrated preclinical proof of concept in non-human primates and humanized mice, showcasing the potential of its gene upregulation strategy across multiple tissues [3][6] - Editas maintains a strong cash position, with cash, cash equivalents, and marketable securities amounting to $269.9 million as of December 31, 2024, which is expected to fund operations into the second quarter of 2027 [4][17] Business Updates - The company achieved in vivo preclinical proof of concept ahead of schedule, indicating significant progress in its gene editing platform [2] - Editas plans to present further preclinical data for HSCs and liver indications by year-end 2025 [1][6] - The company is also on track to establish an additional target cell type or tissue by the end of 2025 [1][6] Financial Performance - For Q4 2024, Editas reported a net loss of $45.4 million, or $0.55 per share, compared to a net loss of $18.9 million, or $0.23 per share, in Q4 2023 [6][14] - Collaboration and other research and development revenues decreased to $30.6 million in Q4 2024 from $60.0 million in Q4 2023, primarily due to revenue recognized from a license agreement with Vertex Pharmaceuticals [6][14] - For the full year 2024, the net loss attributable to common stockholders was $237.1 million, or $2.88 per share, compared to a net loss of $153.2 million, or $2.02 per share, in 2023 [14][15] Restructuring and Cost Management - The company ended the development of its reni-cel program, leading to a workforce reduction of approximately 65% and restructuring charges of $12.2 million in Q4 2024 [6][7] - Research and development expenses decreased to $48.6 million in Q4 2024 from $69.6 million in Q4 2023, primarily due to reduced costs associated with the reni-cel program [6][14] Upcoming Events - Editas Medicine plans to participate in investor events, including the Leerink Partners Global Biopharma Conference and the Barclays 27th Annual Global Healthcare Conference in March 2024 [9]